Lexaria Bioscience Corp. LXRP Archives - Page 9 of 27

TuesdayJun 04, 2019 9:43 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Files Patents for New DehydraTECH Innovation

Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) this morning announced that it has identified improved performance features of a new version of the DehydraTECH(TM) delivery platform primarily suitable for use in solid oral dosage forms like capsules, tablets and pills for the pharmaceutical, medical, and supplement markets. The company’s groundbreaking use of a naturally sourced formulation enhancement more than doubles DehydraTECH's absorption performance compared to prior results. During the company’s animal study, Lexaria tested its DehydraTECH delivery technology with compounds postulated to behave in a synergistic fashion for enhancement of gastro-intestinal absorption, which resulted…

TuesdayMay 28, 2019 10:27 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH(TM) Combined with Nanotech Delivers 1,137 Percent More CBD into Animal Brain Tissue

Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) this morning announced that combining Lexaria's DehydraTECH(TM) delivery technology with generic nanotech techniques has been proven to deliver 1,137% more cannabidiol ("CBD") into animal brain tissue following oral ingestion than certain existing industry formulations. According to the update, the results were confirmed in recent testing based on Lexaria’s series of animal studies it announced that it was beginning on March 20, 2019. Results from the studies with multiple objectives, including developing a better understanding of how effectively edible forms of cannabinoids cross the blood-brain-barrier to enter brain…

TuesdayMay 21, 2019 10:23 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) and Nuka to Expand Cannabis Product Operations for DehydraTECH Powered Edibles

Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) this morning announced that, through a major expansion in operations by Nuka Enterprises LLC, maker of 1906 cannabis edibles for high functioning adults, the most reliable fast acting edibles on the market will now be available across the country. According to the update, Nuka plans to exercise contractual options that it acquired last year for use of DehydraTECH(TM) technology through expanding operations for cannabis chocolates and edibles in six additional states and cannabis beverages in three states in 2019 and 2020. “Nuka's astonishing growth since launch is…

ThursdayMay 16, 2019 12:24 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Responds to High Demand for Cannabis-Infused Beverages

The company aims to promote healthier administration methods, eliminating the need for sweeteners to mask taste Lexaria’s mission is to save lives with its technology, which allows for delivery of drug molecules through ingestible means The company is seeing high demand in North American markets for DehydraTECH in cannabis-infused beverages Lexaria recently announced its entry into a CBD-beverage formulation license agreement with a Nevada-based company Traditionally, consumers have relied on smoking to achieve higher absorption rates and fast onset of bioactive compounds such as nicotine and cannabinoids. Ingesting drugs and molecules through edibles is simply safer than inhaling them. However,…

WednesdayMay 15, 2019 11:25 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH Outperforms Conventional Industry Formulations in Animal Testing

Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) this morning announced that animal testing has proven that its DehydraTECH(TM) technology delivers cannabinoids to the bloodstream much more quickly and effectively than conventional industry formulations. According to the update, 10 male Sprague-Dawley rats were administered CBD at 25mg per kg of bodyweight in each arm of the Lexaria animal studies. Delivery of CBD into the bloodstream was monitored over a 60-minute duration and, at two minutes, 15 minutes, and 60 minutes, DehydraTECH's LCFA formulation delivered elevated levels of CBD in blood (showing measurable and 475% and…

TuesdayMay 14, 2019 12:30 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Adds Four Members to Advisory Board, Renews Executive Contracts

LXRP recently added multiple highly respected experts to its scientific advisory board The company is readying for growth by ensuring executive continuity LXRP continues to conduct research regarding oral nicotine Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has bolstered its future growth prospects by adding four new members to its scientific advisory board and renewing executive contracts with three-year compensation deals for key officers, including CEO Chris Bunka and President John Docherty. The agreements and new advisory board team members offer LXRP and its shareholders seamless executive continuity (http://ibn.fm/oBuUZ). New members of LXRP’s scientific advisory board include (http://ibn.fm/KSdJ3): Dr. Dwayne Godwin, dean…

TuesdayMay 07, 2019 9:41 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Enters CBD-Beverage Formulation License Agreement via Subsidiary

Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) this morning announced its entry into a definitive 5-year agreement, via its subsidiary Lexaria Hemp Corp. Under the agreement, Lexaria will provide its patented DehydraTECH(TM) technology to a private Nevada-based company for utilization in certain CBD-based beverages that will be produced and sold across the U.S. Lexaria continues to experience strong demand for use of its technology for beverage applications in North American markets. Lexaria’s many existing US-granted patents protect DehydraTECH-enabled products, which may include any combination of ready-to-drink beverages such as non-alcoholic beers, wines and spirits,…

MondayMay 06, 2019 10:57 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Enters New Licensing Agreement, Strengthens Business Model

Lexaria continues to create a strong, revenue-generating business model to support its growing patent portfolio The company out-licenses disruptive delivery technology, giving licensees access to existing patents Lexaria entered into a new beverage license agreement with a California-based cannabis firm The company recently announced four new appointments to its scientific advisory board Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is a drug-delivery platform innovator with existing cannabinoid licensing agreements in Canada and the United States, as well as internationally. By out-licensing disruptive delivery technology DehydraTECH, the company has created a strong, revenue-generating business model and a growing patent portfolio. At…

ThursdayMay 02, 2019 11:12 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Execs Sign Three-Year Contract Extensions, Ensuring Management Continuity

LXRP CEO Chris Bunka and President John Docherty have agreed to new, three-year contracts The new contract agreements are designed to provide management security with continuity of key officers The company recently canceled 1,140,000 stock options after negotiations with optionees Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has successfully negotiated new three-year compensation contracts with key officers Chris Bunka, CEO, and John Docherty, president. The agreements offer LXRP and its shareholders the security of pursuing corporate growth within a seamless transition by providing management continuity. The renewal agreements are retroactive to January 1, 2019 (http://ibn.fm/V8SmJ). The agreements offer both officers compensation…

MondayApr 29, 2019 2:05 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Innovative Technology Improves Delivery of Nicotine, Cannabinoids

Biotechnology company and drug-delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has developed and out-licenses its pioneering-drug delivery platform DehydraTECH(TM), which improves the speed, taste and delivery of bioactive compounds, including nicotine and cannabinoids. A recent article discussing the company reads, “Furthermore, the DehydraTECH drug delivery platform increases bio-absorption by up to 10 times and lessens the time of onset, with effects being felt within 15 to 20 minutes, as compared to 60 to 120 minutes without the platform. In addition, the technology is patent protected for cannabidiol (CBD) and all other nonpsychoactive cannabinoids. Patents are also granted…

Site Search

Company Search

Tag: Lexaria Bioscience Corp. LXRP